M F Osti1, L Agolli2, M Valeriani1, C Reverberi1, S Bracci1, L Marinelli1, V De Sanctis1, E Cortesi3, M Martelli4, C De Dominicis5, G Minniti6, L Nicosia7. 1. Department of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Italy. 2. Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 3. Department of Radiology, Oncology and Human Pathology, Policlinico Umberto I "Sapienza" University of Rome, Italy. 4. Thoracic Surgery Unit, Carlo Forlanini Hospital, Rome, Italy. 5. Department of Radiology, Sant'Andrea Hospital, "Sapienza" University of Rome, Italy. 6. Department of Neurological Sciences, IRCCS Neuromed, Via Atinense, Pozzilli, IS, Italy; UPMC San Pietro FBF, Radiotherapy Center, Rome, Italy. Electronic address: giuseppeminniti@libero.it. 7. Department of Radiation Oncology, Sant'Andrea Hospital, "Sapienza" University of Rome, Italy. Electronic address: lucanicosia.rg@gmail.com.
Abstract
OBJECTIVES: To evaluate the local control (LC) and long term adverse effects in a series of patients with lung metastases who received 30 Gy in single dose with stereotactic technique. MATERIALS AND METHODS: Between December 2008 and April 2016, a total of 166 lung metastases in 129 patients affected by oligometastatic disease were treated at our Institution with stereotactic body radiotherapy (SBRT). Mainly, the primary tumors were non small-cell lung cancer and colorectal cancer (45.2% and 28.8%, respectively). Prognostic factors were also assessed. RESULTS: The median follow-up was 38 months. Local progression occurred in 24 (14.4%) lesions in 21 patients. Intra-thoracic progression (new lung lesions or thoracic lymph node metastases) occurred in 59 (45.7%) patients. Forty-five (34.8%) patients had distant progression after a median time of 14 months. The 3- and 5-years local relapse-free survival (LPFS) were 80.1% and 79.2% (median not reached), respectively. One-hundred forty-eight patients were evaluated for late toxicity (follow-up >6 months): 51 (34.4%) patients had grade ≤2 fibrosis, 11 (7.4%) patients experienced grade 3 fibrosis. Two (1.3%) cases of rib fracture occurred. One case of toxic death (grade 5) has been reported. Median OS was 39 months. At the univariate analysis, lesion diameter ≤18 mm correlated significantly with a longer LPFS (p = 0.001). At the multivariate analysis, lesion diameter <18 mm was predictive for longer LPFS (p = 0.006). Also, oligometastases from primary colorectal cancer was a significant predictive factor for worse LPFS (p = 0.041) and progression-free survival (p = 0.04). CONCLUSIONS: To our knowledge, the current study represents the largest series on the use of SBRT 30 Gy single dose for lung metastases. Our results confirm the effectiveness and safety of this schedule administered in selected oligometastatic patients. Further prospective series could better validate these results.
OBJECTIVES: To evaluate the local control (LC) and long term adverse effects in a series of patients with lung metastases who received 30 Gy in single dose with stereotactic technique. MATERIALS AND METHODS: Between December 2008 and April 2016, a total of 166 lung metastases in 129 patients affected by oligometastatic disease were treated at our Institution with stereotactic body radiotherapy (SBRT). Mainly, the primary tumors were non small-cell lung cancer and colorectal cancer (45.2% and 28.8%, respectively). Prognostic factors were also assessed. RESULTS: The median follow-up was 38 months. Local progression occurred in 24 (14.4%) lesions in 21 patients. Intra-thoracic progression (new lung lesions or thoracic lymph node metastases) occurred in 59 (45.7%) patients. Forty-five (34.8%) patients had distant progression after a median time of 14 months. The 3- and 5-years local relapse-free survival (LPFS) were 80.1% and 79.2% (median not reached), respectively. One-hundred forty-eight patients were evaluated for late toxicity (follow-up >6 months): 51 (34.4%) patients had grade ≤2 fibrosis, 11 (7.4%) patients experienced grade 3 fibrosis. Two (1.3%) cases of rib fracture occurred. One case of toxic death (grade 5) has been reported. Median OS was 39 months. At the univariate analysis, lesion diameter ≤18 mm correlated significantly with a longer LPFS (p = 0.001). At the multivariate analysis, lesion diameter <18 mm was predictive for longer LPFS (p = 0.006). Also, oligometastases from primary colorectal cancer was a significant predictive factor for worse LPFS (p = 0.041) and progression-free survival (p = 0.04). CONCLUSIONS: To our knowledge, the current study represents the largest series on the use of SBRT 30 Gy single dose for lung metastases. Our results confirm the effectiveness and safety of this schedule administered in selected oligometastatic patients. Further prospective series could better validate these results.
Authors: F Alongi; L Nicosia; V Figlia; V De Sanctis; R Mazzola; N Giaj-Levra; C Reverberi; M Valeriani; M F Osti Journal: Clin Transl Oncol Date: 2021-04-10 Impact factor: 3.405
Authors: Matthew P Deek; Colburn Yu; Ryan Phillips; Daniel Y Song; Curtiland Deville; Stephen Greco; Theodore L DeWeese; Emmanuel S Antonarakis; Mark Markowski; Channing Paller; Samuel Denmeade; Michael Carducci; Patrick C Walsh; Kenneth J Pienta; Mario Eisenberger; Phuoc T Tran Journal: Int J Radiat Oncol Biol Phys Date: 2019-08-13 Impact factor: 7.038
Authors: Guillaume Virbel; David G Cox; Anne Olland; Pierre-Emmanuel Falcoz; Clara Le Fevre; Roland Schott; Delphine Antoni; Georges Noel Journal: Front Oncol Date: 2022-07-18 Impact factor: 5.738